萝藦科马利筋族植物化学成分研究进展(Ⅱ)

综述了到目前为止,从马利筋族植物中发现的黄酮、强心甙、生物碱、萜类、苯衍生物类等成分的种类及其分布,并介绍了一些化合物的药理作用以及黄酮类和C21甾体化合物在鹅绒藤属化学分类中的作用.     

Anti-apoptotic and Anti-oxidative Roles of Quercetin After Traumatic Brain Injury

Experimental studies have demonstrated significant secondary damage (including cell apoptosis, blood–brain barrier disruption, inflammatory responses, excitotoxic damage, and free radical production) after traumatic brain injury (TBI). Quercetin is a natural flavonoid found in high quantities in fruits and vegetables, and may be a potential antioxidant and free radical scavenger. The purpose of this study was to determine the effects of quercetin on TBI-induced upregulation of oxidative stress, inflammation, and apoptosis in adult Sprague–Dawley rats. Animals were subjected to Feeney’s weight-drop injury, thus inducing the parietal contusion brain injury model. Quercetin was administered (30 mg/kg intraperitoneal injection) 0, 24, 48, and 72 h after TBI. Quercetin reduced cognitive deficits, the number of TUNEL- and ED-1-positive cells, the protein expressions of Bax and cleaved-caspase-3 proteins, and the levels of TBARS and proinflammatory cytokines, and increased the activity of antioxidant enzymes (GSH-Px, SOD, and CAT) at 1 week after TBI. Our results suggest that in TBI rats, quercetin improves cognitive function owing to its neuroprotective action via the inhibition of oxidative stress, leading to a reduced inflammatory response, thereby reducing neuronal death.     

七个中药复方对小鼠止咳化痰作用的对比实验

目的为了筛选出防治猪呼吸道疾病综合征(PRDC)有效的中药复方制剂,对七个具有止咳化痰作用的中药复方制剂进行了对比实验。方法以小鼠为实验动物,用右美沙芬、氯化铵作阳性药,生理盐水作空白对照,采用浓氨水引咳法和气管段酚红分泌法,对七个中药复方制剂的止咳化痰作用进行了观测。结果方7、方5可显著延长小鼠的咳嗽潜伏期(P0.05),减少5 min内的咳嗽次数(P0.05),除方4组外,其他中药组的气管酚红排泌量显著低于对照组(P0.05),并且方7、方5和氯化铵组小鼠的酚红排泌量显著低于其他处理组(P0.05)。结论七个中药复方组中,方5、方7的止咳化痰作用最显著,可在进一步实验研究后,作为PRDC的治疗药物。     

Rab1 interacts directly with the β2-adrenergic receptor to regulate receptor anterograde trafficking

Very little is understood about the trafficking of G protein-coupled receptors (GPCRs) from the endoplasmic reticulum (ER) to the plasma membrane. Rab guanosine triphosphatases (GTPases) are known to participate in the trafficking of various GPCRs via a direct interaction during the endocytic pathway, but whether this occurs in the anterograde pathway is unknown. We evaluated the potential interaction of Rab1, a GTPase known to regulate β2-adrenergic receptor (β2AR) trafficking, and its effect on export from the ER. Our results show that GTP-bound Rab1 interacts with the F(x)(6)LL motif of β2AR. Receptors lacking the interaction motif fail to traffic properly, suggesting that a direct interaction with Rab1 is required for β2AR anterograde trafficking.     

鬼臼毒素涂膜剂治疗子宫颈HPV 感染的疗效观察

目的:了解鬼臼毒素涂膜剂治疗子宫颈HPV感染的疗效。方法:126例临床诊断证明为子宫颈HPV感染的患者,随机分为两组,试验组63例采用0.5%鬼臼毒素涂膜剂治疗,对照组63例单独采用0.5%鬼臼毒素酊治疗。结果:①痊愈率:试验组与对照组的痊愈率分别为90.5%、73.00%,两组比较具有统计学学差异(P<0.05);②复发率:试验组与对照组第12、24周的复发率分别为9.52%、28.57%和9.52%、36.51%,两个时段的两组比较均具有统计学差异(P<0.05);③不良反应:经随访观察,两组发生了红斑、水肿、灼热、疼痛、瘙痒、溃疡、渗出等不良反应,其中两组比较试验组红斑、水肿、溃疡、渗出的发生率低于对照组,具有统计学差异(P<0.05)。结论:鬼臼毒素涂膜剂能有效治疗子宫颈HPV感染,并控制复发,副作用小,比采用鬼臼毒素酊治疗的效果好。     

Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCR-ABL kinase

A series of acrylamide analogues were designed and synthesized from Imatinib and Nilotinib as novel BCR-ABL inhibitors by application of the principle of nonclassical electronic isostere. All new compounds were evaluated for their inhibitory effects on the activity of BCR-ABL kinase and the proliferation of K562 leukemia cancer cells in vitro. The acrylamide analogues in which the substituent in C ring was trifluoromethyl group were identified as highly potent BCR-ABL kinase inhibitors. Compound 13f exhibited an IC(50) value as low as 20.6nM in ABL kinase inhibition and an IC(50) value of 32.3nM for antiproliferative activity, about 10.5-fold and 12-fold lower than those of Imatinib respectively. These results suggest that compound 13f is a promising candidate as a novel BCR-ABL kinase inhibitor for further development.     

Proteases in malaria parasites - a phylogenomic perspective

Malaria continues to be one of the most devastating global health problems due to the high morbidity and mortality it causes in endemic regions. The search for new antimalarial targets is of high priority because of the increasing prevalence of drug resistance in malaria parasites. Malarial proteases constitute a class of promising therapeutic targets as they play important roles in the parasite life cycle and it is possible to design and screen for specific protease inhibitors. In this mini-review, we provide a phylogenomic overview of malarial proteases. An evolutionary perspective on the origin and divergence of these proteases will provide insights into the adaptive mechanisms of parasite growth, development, infection, and pathogenesis.B.     

Mechanism of inhibition of retrovirus release from cells by interferon-induced gene ISG15

Budding of retroviruses from cell membranes requires ubiquitination of Gag and recruitment of cellular proteins involved in endosome sorting, including endosome sorting complex required for transport III (ESCRT-III) protein complex and vacuolar protein sorting 4 (VPS4) and its ATPase. In response to infection, a cellular mechanism has evolved that blocks virus replication early and late in the budding process through expression of interferon-stimulated gene 15 (ISG15), a dimer homologue of ubiquitin. Interferon treatment of DF-1 cells blocks avian sarcoma/leukosis virus release, demonstrating that this mechanism is functional under physiological conditions. The late block to release is caused in part by a loss in interaction between VPS4 and its coactivator protein LIP5, which is required to promote the formation of the ESCRT III-VPS4 double-hexamer complex to activate its ATPase. ISG15 is conjugated to two different LIP5-ESCRT-III-binding charged multivesicular body proteins, CHMP2A and CHMP5. Upon ISGylation of each, interaction with LIP5 is no longer detected. Two other ESCRT-III proteins, CHMP4B and CHMP6, are also conjugated to ISG15. ISGylation of CHMP2A, CHMP4B, and CHMP6 weakens their binding directly to VPS4, thereby facilitating the release of this protein from the membrane into the cytosol. The remaining budding complex fails to release particles from the cell membrane. Introducing a mutant of ISG15 into cells that cannot be conjugated to proteins prevents the ISG15-dependent mechanism from blocking virus release. CHMP5 is the primary switch to initiate the antiviral mechanism, because removal of CHMP5 from cells prevents ISGylation of CHMP2A and CHMP6.